ArticleFrontiers in oncology2023
By using machine learning and
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Identification of Pyroptosis-Related Genes and Immune Landscape in Myocardial Ischemia-Reperfusion Injury.Biomedicines · 2025Article
- Identification of endothelial INSR as an osteosarcoma-related biomarker and therapeutic target based on weighted gene co-expression network analysis.Discover oncology · 2025Article
- Prognostic and Therapeutic Significance of Cancer-Associated Fibroblasts Genes in Osteosarcoma Based on Bulk and Single-Cell RNA Sequencing Data.Journal of cellular and molecular medicine · 2025Article
- WNT inhibitor SP5-mediated SERPING1 suppresses lung adenocarcinoma progression via TSC2/mTOR pathway.Cell death & disease · 2025Article
- Review
- SERPINH1 functions as a multifunctional regulator to promote the malignant progression of cervical cancer.PloS one · 2025Article
- A multi-cohort validated OXPHOS signature predicts survival and immune profiles in grade II/III glioma patients.Frontiers in immunology · 2025Article
- Identification of the shared gene signatures in retinoblastoma and osteosarcoma by machine learning.Scientific reports · 2024Article
- Deciphering the prognostic role of endoplasmic reticulum stress in lung adenocarcinoma: integrating prognostic prediction and immunotherapy strategies.Clinical and experimental medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The most prevalent bone tumor with a relatively high level of aggressiveness and malignancy is osteosarcoma. The characteristics of the serpin family in osteosarcoma have not been defined. Methods: In this study, the predictive significance of the serpin superfamily was investigated in the osteosarcoma and Gene Expression Omnibus (GEO) databases from The Cancer Genome Atlas (TCGA). Results: It was discovered that SERPINH1 is a significant biological marker in osteosarcoma. According to the CCK-8, EdU, and Transwell assays as well as the IHC assay, SERPINH1 may promote osteosarcoma proliferation and migration. It is also more expressed in tumor samples than in healthy samples. SERPINH1 might forecast the effects of immunotherapy. Additionally, immune cells are interacted with through checkpoint, cytokine, and growth factor pathways in osteosarcomas with high SERPINH1 levels. The biological function, immunological characteristics, and treatment response (immunotherapy and chemotherapy responses) of patients with osteosarcoma were successfully predicted using a model related to SERPINH1. SERPINH1 and the SERPINH1-related score predict ferroptosis/pyroptosis/apoptosis/necroptosis in osteosarcoma. Discussion: The SERPINH1-related score was an effective method for identifying osteosarcoma patients who would respond to immunotherapy and chemotherapy, as well as for predicting the survival outcomes of such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.